RAYMOND JAMES & ASSOCIATES - BRAINSTORM CELL THERAPEUTICS ownership

BRAINSTORM CELL THERAPEUTICS's ticker is BCLI and the CUSIP is 10501E201. A total of 45 filers reported holding BRAINSTORM CELL THERAPEUTICS in Q3 2022. The put-call ratio across all filers is 0.11 and the average weighting 0.0%.

Quarter-by-quarter ownership
RAYMOND JAMES & ASSOCIATES ownership history of BRAINSTORM CELL THERAPEUTICS
ValueSharesWeighting
Q3 2023$27,586
-91.9%
137,860
-16.2%
0.00%
Q2 2023$339,082
-37.6%
164,603
-0.1%
0.00%
Q1 2023$543,520
+55.8%
164,703
-22.6%
0.00%
Q4 2022$348,833
-67.8%
212,703
-13.1%
0.00%
-100.0%
Q3 2022$1,082,000
+109.3%
244,803
+30.6%
0.00%0.0%
Q2 2022$517,000
-19.2%
187,403
-1.6%
0.00%0.0%
Q1 2022$640,000
-15.6%
190,403
+0.5%
0.00%0.0%
Q4 2021$758,000
+14.8%
189,503
-11.4%
0.00%0.0%
Q3 2021$660,000
-13.0%
213,768
+7.0%
0.00%0.0%
Q2 2021$759,000
+0.9%
199,743
-9.5%
0.00%0.0%
Q1 2021$752,000
-52.1%
220,678
-36.4%
0.00%
-50.0%
Q4 2020$1,570,000
-67.9%
347,006
+20.2%
0.00%
-66.7%
Q3 2020$4,884,000
+71.4%
288,675
+13.6%
0.01%
+50.0%
Q2 2020$2,849,000
+205.7%
254,175
+26.5%
0.00%
+300.0%
Q1 2020$932,000
+79.2%
200,950
+65.3%
0.00%0.0%
Q4 2019$520,000
+53.8%
121,600
+40.3%
0.00%
Q3 2019$338,00086,7000.00%
Other shareholders
BRAINSTORM CELL THERAPEUTICS shareholders Q3 2022
NameSharesValueWeighting ↓
SABBY MANAGEMENT, LLC 242,850$923,0000.13%
ABNER HERRMAN & BROCK LLC 241,500$918,0000.13%
Weaver Consulting Group 48,881$186,0000.10%
Tibra Equities Europe Ltd 87,000$331,0000.10%
Ikarian Capital, LLC 293,200$1,115,0000.09%
GSA CAPITAL PARTNERS LLP 60,238$229,0000.03%
Ergoteles LLC 124,329$472,0000.01%
CFO4Life Group, LLC 12,003$46,0000.01%
HighPoint Advisor Group LLC 17,033$65,0000.01%
BOOTHBAY FUND MANAGEMENT, LLC 32,836$125,0000.00%
View complete list of BRAINSTORM CELL THERAPEUTICS shareholders